E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pigmented villonodular synovitis (PVNS) / giant cell tumour of tendon sheath (GCT-TS) |
|
E.1.1.1 | Medical condition in easily understood language |
Tumour of the tendon sheath |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10062856 |
E.1.2 | Term | Giant cell tumour of tendon sheath benign |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to compare the response rate of PLX3397 with that of placebo per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) at Week 25 in subjects with symptomatic, locally advanced PVNS or GCT-TS. |
|
E.2.2 | Secondary objectives of the trial |
The secondary efficacy objectives are to evaluate: (i) patient-reported outcomes (PROs), including the Brief Pain Inventory (BPI) Worst Pain Numeric Rating Scale (NRS) item, Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function Scale, and Worst Stiffness NRS item, at Week 25; (ii) response based on TVS at Week 25; (iii) range of motion at Week 25; and (iv) duration of response. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age ≥ 18 years. 2. A diagnosis of PVNS or GCT-TS (i) that has been histologically confirmed either by a pathologist at the treating institution or a central pathologist, and (ii) where surgical resection would be associated with potentially worsening functional limitation or severe morbidity (locally advanced disease), with morbidity determined consensually by qualified personnel (eg, two surgeons or a multi-disciplinary tumor board). 3. Measurable disease as defined by RECIST 1.1 (except that a minimal size of 2cm is required) , assessed from MRI scans by a central radiologist. 4. Symptomatic disease because of active PVNS or GCT-TS, defined as one or more of the following: a. a worst pain of at least 4 at any time during the week preceding the screening visit (based on scale of 0 to 10, with 10 representing "pain as bad as you can imagine"). b. a worst stiffness of at least 4 at any time during the week preceding the screening visit (based on a scale of 0 to 10, with 10 representing "stiffness as bad as you can imagine"). 5. Stable prescription of analgesic regimen during the 2 weeks prior to randomization. 6. During the 2 weeks prior to randomization, at least 4 of 7 consecutive days of BPI Worst Pain NRS items and Worst Stiffness NRS items completed correctly. 7. Women of childbearing potential must have a negative serum pregnancy test within the 14-day period prior to randomization. (Where demanded by local regulations, this test may be required within 72 hours of randomization.) 8. Male and female subjects of childbearing potential are permitted in the study so long as they consent to avoid getting their partner pregnant or becoming pregnant, respectively, by using a highly effective contraception method, as described below, throughout the study and for up to 90 days after completion. Highly effective methods of contraception include: hormonal methods associated with inhibition of ovulation, intra-uterine device; surgical sterilization (including partner's vasectomy) or sexual abstinence. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year. Women who have documentation of at least 12 months of spontaneous amenorrhea and have an FSH level >40 mIU/mL will be considered postmenopausal. 9. Adequate hematologic, hepatic, and renal function, defined by: • Absolute neutrophil count ≥ 1.5 × 109/L • AST/ALT ≤ 1.5 × ULN • Hemoglobin > 10 g/dL • Total bilirubin ≤ 1.5 × ULN • Platelet count ≥ 100 × 109/L • Serum creatinine ≤ 1.5 × ULN 10. Willingness and ability to complete the BPI Worst Pain NRS item, Worst Stiffness NRS item, PROMIS Physical Function Scale, and other self-assessment instruments throughout the study. 11. Willingness and ability to use an electronic diary. 12. Willingness and ability to provide written informed consent prior to any study-related procedures and to comply with all study requirements. |
|
E.4 | Principal exclusion criteria |
1. Investigational drug use within 28 days of randomization. 2. Previous use of pexidartinib or any biologic treatment targeting CSF-1 or the CSF1R; previous use of oral tyrosine kinase inhibitors, eg, imatinib or nilotinib, are allowed. 3. Active cancer (either concurrent or within the last year of starting study treatment) that requires therapy (eg, surgical chemotherapy or radiation therapy), with the exception of adequately treated basal or squamous cell carcinoma of the skin, melanoma in-situ, or carcinoma insitu of the cervix or breast or prostrate carcinoma with a prostrate specific antigen value <0.2 ng/mL. 4. Known metastatic PVNS/GCT-TS. 5. Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus. 6. Known active tuberculosis. 7. Significant concomitant arthropathy in the affected joint, serious illness, uncontrolled infection, or a medical or psychiatric history that, in the investigator's opinion, would likely interfere with the person's study participation or the interpretation of his or her results. 8. Women who are breastfeeding. 9. A screening Fridericia corrected QT interval (QTcF) ≥ 450 ms (men) or ≥ 470 ms (women). 10. MRI contraindications. 11. History of hypersensitivity to any excipients in the investigational product 12. Inability to swallow capsules. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The proportion of subjects who achieve a complete or partial response at the Week 25 visit based on centrally read MRI scans and RECIST 1.1. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. Proportion of responders based on the BPI Worst Pain NRS item and analgesic use by BPI-30 definition (as defined in Section 7.6.2) 2. Proportion of responders based on centrally evaluated MRI scans and TVS at the Week 25 visit 3. Mean change from baseline in range of motion of the affected joint, relative to a reference standard for the same joint, at the Week 25 visit 4. Mean change from baseline score in the PROMIS Physical Function Scale at the Week 25 visit 5. Mean change from baseline score in the Worst Stiffness NRS item at the Week 25 visit 6. Duration of response (CR or PR) based on MRI and RECIST 1.1 7. Duration of response (CR or PR) based on MRI and TVS |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 18 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
Denmark |
France |
Germany |
Hungary |
Italy |
Netherlands |
Poland |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |